Eli Lilly and Company (Lilly) has signed a deal worth at least $720 million with the US government to deliver up to 600,000 doses of bebtelovimab, its investigational drug for Covid-19. According to Lilly, the US government will accept the doses of bebtelovimab if it secures an emergency use authorization (EUA) from the US Food […]
Eli Lilly and Company (Lilly) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for bebtelovimab for the treatment of mild-to-moderate Covid-19. According to Lilly, bebtelovimab is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2, which has also shown capability to neutralize against the Omicron […]